Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and Company Provides Tirzepatide Results

10/19/2021 | 06:45am EST

Eli Lilly and Company's provided results that Adults with type 2 diabetes with increased cardiovascular risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine. At 52 weeks, the highest dose of tirzepatide led to an A1C reduction of 2.58 % and reduced body weight by 11.7 kg compared to results for those treated with insulin glargine. SURPASS-4 is the largest and longest clinical trial completed to date of the phase 3 program studying tirzepatide as a potential treatment for type 2 diabetes. The primary endpoint was measured at 52 weeks, with participants continuing treatment up to 104 weeks or until study completion. The completion of the study was triggered by the accrual of major adverse cardiovascular events to assess CV risk. In newly published data from the treatment period after 52 weeks, participants taking tirzepatide maintained A1C and weight control for up to two years. The overall safety profile of tirzepatide, assessed over the full study period, was consistent with the safety results measured at 52 weeks, with no new findings up to 104 weeks. Gastrointestinal side effects were the most commonly reported adverse events, usually occurring during the escalation period and then decreasing over time. Tirzepatide is a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist that integrates the actions of both incretins into a single molecule, representing a new class of medicines being studied for the treatment of type 2 diabetes. SURPASS-4 was an open-label global trial comparing the safety and efficacy of three tirzepatide doses to titrated insulin glargine in 2,002 adults with type 2 diabetes with increased CV risk who were treated with between one and three oral antihyperglycemic medicines. Of the total participants randomized, 1,819 completed the primary 52-week visit and 1,706 completed the study on treatment. The median study duration was 85 weeks and 202 participants completed two years. Study participants had a mean duration of diabetes of 11.8 years, a baseline A1C of 8.52% and a baseline weight of 90.3 kg. More than 85% of participants had a history of cardiovascular events. In the insulin glargine arm, the insulin dose was titrated following a treat-to-target algorithm with the goal of fasting blood glucose below 100 mg/dL. The starting dose of insulin glargine was 10 units per day, and the mean dose of insulin glargine at 52 weeks was 43.5 units per day. Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight. Tirzepatide is in phase 3 development for blood glucose management in adults with type 2 diabetes, for chronic weight management and heart failure with preserved ejection fraction. It is also being studied as a potential treatment for non-alcoholic steatohepatitis.


ę S&P Capital IQ 2021
All news about ELI LILLY AND COMPANY
11/24Truist Securities Adjusts Eli Lilly and Co.'s Price Target to $301 from $262, Keeps Buy..
MT
11/19BMO Capital Starts Eli Lilly at Outperform With $311 Price Target
MT
11/18Emgality Versus Nurtec ODT Head-To-Head Migraine Preventive Treatment Study Now Enrolli..
CI
11/18Fountain Therapeutics, Inc. announced that it has received $15 million in funding from ..
CI
11/17Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference
PR
11/17PharmStars Announces Showcase Event for Inaugural Class
AQ
11/12REFILE-UPDATE 4-Biden will nominate industry-friendly Califf to lead U.S. FDA
RE
11/12Dicerna Pharmaceuticals to Receive Multimillion-Dollar Milestone Payments Under Collabo..
MT
11/12Lilly to supply 614,000 additional doses of abcellera, discovered bamlanivimab together..
AQ
11/12DICERNA PHARMA : Two Targets in Lilly Collaboration Meet Proof of Principle
DJ
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 480 M - -
Net income 2021 6 300 M - -
Net Debt 2021 12 164 M - -
P/E ratio 2021 37,2x
Yield 2021 1,29%
Capitalization 231 B 231 B -
EV / Sales 2021 8,85x
EV / Sales 2022 8,64x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 254,83 $
Average target price 273,42 $
Spread / Average Target 7,30%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY54.21%236 049
JOHNSON & JOHNSON1.16%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ABBVIE INC.8.74%205 976